论文部分内容阅读
本报告是取代以前的有关美国控制结核（ＴＢ）的卡介苗（ＢＣＧ）的建议的最新资料。自从以前的建议公布后，在成人和儿童中的ＴＢ病例数有所上升，而且在医院内出现了多种耐药结核的暴发。另外，也有了关于ＢＣＧ的保护作用的资料，例如，所公布的ＢＣＧ疫苗临床试验的结果和病例对照研究的两个交互分析（ｍｅｔａ－ａｎａｌｙｓｅｓ），进一步确证对预防儿童严重类型的ＴＢ，ＢＣＧ的保护功效是很大的（即，＞８０％）。然而，这些分析不能说明ＢＣＧ对预防青少年和成人的肺ＴＢ的保护功效，这种保护功效是变化不定的、不肯定的。公共卫生社区关心的美国ＴＢ的复更生和正在改变的特性，敦促了在预防和控制ＴＢ中ＢＣＧ接种作用的再评价。这次最新的报告由ＣＤＣ、消除结核咨询委员会、和预防接种咨询委员会发布的，是与医院感染控制工作咨询委员会共同磋商而写出的。它概述了有关美国ＢＣＧ疫苗使用当前的考虑和建议
This is the latest update to replace the previous recommendation on the United States BCG (TB) control. Since the previous recommendations were announced, the number of TB cases in adults and children has risen, and there have been many outbreaks of drug-resistant TB in hospitals. In addition, there is also information on the protective effects of BCG such as the published meta-analyzes of the results of the BCG vaccine clinical trial and the case-control study, further confirming the efficacy against BCG of severe forms of childhood Protection is great (ie,> 80%). However, these analyzes do not explain the protective efficacy of BCG against lung TB in adolescents and adults, and the protective efficacy is variable and uncertain. The renewed and changing characteristics of the U.S. TB care of the public health community have prompted the reevaluation of BCG vaccination in the prevention and control of TB. The latest report, released by the CDC, the TB TB Advisory Committee and the Vaccinations Advisory Committee, was prepared in consultation with the Hospital Infection Control Advisory Committee. It outlines the current considerations and recommendations regarding the use of BCG vaccines in the United States